A Ghanaian herbal preparation, Vikil 20, produced by Joy Industries Limited, has attracted scientific attention following laboratory findings that indicate its potential to inhibit the growth of prostate cancer cells and neutralize free radicals.
The findings, published in the peer-reviewed journal Integrative Cancer Therapies on May 9, 2024, have opened a fresh avenue for investigating Ghana’s indigenous medicinal resources and their possible contribution to future cancer research.
The research, conducted by scientists affiliated with the University of Health and Allied Sciences (UHAS) in Ho and the Centre for Plant Medicine Research at Mampong, examined the antioxidant properties of Vikil 20 and its effects on prostate cancer cells under controlled laboratory conditions.
Professor Clement Okraku Tettey, the lead researcher and Head of Department at UHAS, presented the findings at the Third Scientific Conference of the Ghana Armed Forces Health Service in 2026, on Wednesday, bringing renewed attention to the importance of scientific research into locally developed herbal preparations.
The conference, held on the theme “From Evidence to Impact: Bridging the Gap Between Research, Policy and Practice,” attracted academics, medical practitioners, traditional authorities and other stakeholders.
The findings have strengthened the case for sustained investment in medicinal plant research, particularly in a country where traditional medicine remains an important part of the healthcare landscape.
JOY INDUSTRIES AND THE VIKIL 20 STORY
Vikil 20 is marketed as a Ghanaian herbal preparation for immune support and general wellbeing. Joy Industries Limited is a Ghanaian company whose business activities include herbal medicines and other consumer products. Vikil 20 is among the herbal preparations associated with the business and is sold through pharmacies and other retail outlets.
The scientific investigation into the product therefore represents an opportunity to examine whether a commercially available Ghanaian herbal preparation contains compounds that could be relevant to future pharmaceutical research.
However, the discovery of potentially useful biological properties does not, by itself, establish that the product can prevent or treat cancer. Nor does it establish that its manufacturer has developed a clinically proven anticancer medicine.
Further information from the company on its manufacturing processes, quality-control systems, research partnerships and regulatory status would help provide a fuller picture of the product’s development and commercial history.
THREE INDIGENOUS PLANTS UNDER INVESTIGATION
The scientific paper identifies three plant ingredients in Vikil 20: Khaya senegalensis, Azadirachta indica, commonly known as neem, and Vernonia amygdalina, popularly called bitter leaf.
These plants have a history of use in traditional medicine, but their presence in an herbal formulation does not automatically establish its safety or effectiveness against a particular disease. The researchers investigated the preparation’s antioxidant activity using laboratory assays designed to measure its ability to neutralize free radicals.
At the highest concentration tested, Vikil 20 neutralized 57.61 per cent of DPPH radicals and 92.88 per cent of ABTS radicals. The results indicated substantial activity in the two antioxidant tests, prompting further interest in the formulation’s biological properties.
Oxidative stress, which occurs when free radicals overwhelm the body’s antioxidant defenses, has been associated with several disease processes, including mechanisms involved in cancer development.
Nevertheless, the researchers’ findings do not establish that consuming Vikil 20 reduces the risk of developing prostate cancer in humans.
Prostate cancer cells show reduced viability
One of the study’s key findings concerned PC-3 cells, a laboratory cell line used in prostate cancer research. After 48 hours of exposure to the herbal preparation, cancer-cell viability fell to approximately 50.5 per cent at the highest concentration tested.
The researchers also observed significant inhibition of cancer-cell movement and attachment, two processes investigated in studies of cancer invasion and the potential spread of malignant cells.
In addition, the preparation produced a modest reduction in the secretion of tumor necrosis factor-alpha, a signaling protein involved in inflammation and biological processes associated with cancer progression.
The study reported no comparable reduction in the viability of the non-cancerous cells used for comparison. This raised the possibility of a selective effect on cancer cells, although additional studies are needed to establish whether that effect is reproducible and safe in living organisms.
These findings are scientifically relevant because they identify several biological responses that researchers can investigate further.
However, experiments involving isolated cells cannot predict with certainty how an herbal preparation will behave inside the human body, where absorption, metabolism, dosage and interactions with other substances can influence its effects.
Government support could advance indigenous medicinal research
The findings present an opportunity for Ghana to strengthen investment in research into medicinal plants and locally developed herbal products.
Government agencies, universities, research institutions and private manufacturers could collaborate to investigate the active compounds in promising preparations, assess their safety and determine whether the initial laboratory findings can be replicated.
Such collaboration could also support the development of local scientific expertise, improved quality-control procedures and stronger evidence-based approaches to traditional medicine. For a company such as Joy Industries, further independent research could help establish a clearer scientific understanding of Vikil 20’s composition, consistency and biological properties.
Any future claims about cancer prevention or treatment would, however, need to be supported by appropriate preclinical studies and carefully designed clinical trials involving human participants. Investment in such research would help distinguish promising laboratory observations from products whose clinical benefits have been established.
Scientific caution over cancer-prevention claims
Despite the encouraging findings, the study does not prove that Vikil 20 prevents, treats or cures prostate cancer in humans. The experiments were conducted on cells in a laboratory, not on patients. The product’s effectiveness, appropriate dosage, long-term safety and possible interactions with conventional medicines remain to be established through further research.
Patients should therefore not substitute Vikil 20 for established prostate cancer screening, diagnosis or treatment.
The research nevertheless demonstrates why Ghanaian herbal preparations deserve rigorous scientific investigation rather than being accepted or dismissed solely on the basis of traditional use or commercial claims.
For Joy Industries Limited, the findings place Vikil 20 within an important scientific discussion about the potential of indigenous medicinal resources. For Ghana, they reinforce the need to support research capable of determining whether promising plant-based preparations can eventually contribute to safe, effective and evidence-based healthcare.
The next phase of investigation will be crucial in determining whether the observed laboratory effects can translate into any meaningful benefit for patients.
For more news, join The Chronicle Newspaper channel on WhatsApp: https://whatsapp.com/channel/0029VbBSs55E50UqNPvSOm2z
